-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Read only for medical professionals Reference clinical decision-making can be made simpler On April 21, 2022, the World Health Organization (WHO) updated the guidelines for COVID-19 treatment in the British Medical Journal (BMJ), one of the four leading medical journals.
Guideline update [1], this guideline was first published in 2020
.
The updated guideline is very detailed and comprehensive, it assembles all key clinical trial evidence and relevant literature, especially the SOLIDARITY study conducted by WHO itself, and summarizes the treatment of COVID-19 in one figure (strongly recommended)
.
(General picture of WHO recommendation table) Highlight 1: Mild treatment, these 5 types of drugs are recommended In the latest WHO guidelines, for mild patients, the recommended and not recommended drugs are sorted as follows: The only important recommended treatment is Pfizer's Paxlovid; Conditions recommended are Molnupiravir, Remdesivir, and monoclonal antibodies Sotrovimab and REGN-COV2; ivermectin and cortisol hormone therapy are not recommended; the use of convalescent plasma, hydroxychloroquine and lopinavir is strongly discouraged Ritonavir tablets
.
(For the evaluation of Remdesivir) Highlight 2: Drug use in severe and critically ill patients For severe patients with pneumonia and hypoxia: Cortisol hormones, IL-6 inhibitors and JAK inhibitor Baricitinib are strongly recommended; but JAK1 is not recommended /2 inhibitors Ruxolitinib and Tofacitinib, ivermectin and convalescent serum; strongly against the use of hydroxychloroquine and lopinavir-ritonavir tablets
.
For critically ill patients with ARDS: cortisol hormone therapy only recommended; JAK1/2 inhibitors Ruxolitinib and Tofacitinib, ivermectin and convalescent serum not recommended; hydroxychloroquine and lopinavir-ritonavir are strongly discouraged slice
.
(Recommendation for hormones) Highlight 3: Paxlovid's medication indications and precautions The most important thing for this updated guideline is a comprehensive introduction to the use of Pfizer's Paxlovid indications, relevant evidence and precautions (see the figure below)
.
(For Paxlovid's evaluation) References: [1] https:// The original guideline, download the Doctor Station App and get it for free Source: Hanson Clinical Research Author: Dr.
Wang Yuge Editor-in-Chief : Tian Wei proofread: Zang Hengjia's wonderful review of past issues confirmed that 3 injections of these two vaccines can prevent severe illness and death, and the protective power exceeds 97%! Can infection with the new crown be more protective than vaccination? Large-scale real-world research releases six mysteries of the new crown epidemic, when will they be solved? * The medical community strives for the accuracy and reliability of its published content when it is approved, but does not make any commitments and guarantees about the timeliness of the published content, and the accuracy and completeness of the cited materials (if any), and does not assume any any liability arising out of the date of such content, possible inaccuracies or incompleteness of the material cited
.
Relevant parties are requested to check separately when adopting or using it as a basis for decision-making
.